[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Yanada S, Ito H, Tomita M, Wada T, Hatano T, Kishimoto K, Egawa S: [A case of recurrent metastatic testicular cancer, successfully treated with paclitaxel, ifomide and cisplatin]. Hinyokika Kiyo; 2008 Jan;54(1):43-6
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent metastatic testicular cancer, successfully treated with paclitaxel, ifomide and cisplatin].
  • A 30-year-old man was diagnosed with testicular cancer, and underwent a radical orchiectomy.
  • Pathological diagnosis was a mixed type nonseminomatous germ cell tumor.
  • We diagnosed him as having stage I testicular cancer and decided to forgo adjuvant therapy.
  • After 8 months of follow-up, he was admitted to our department because of brain, lung, and spleen metastases.
  • Since the serum alpha-fetoprotein (AFP) level was present at a high level at 1,297 ng/ml, he was given combination chemotherapy consisting of 3 cycles of PEB, cisplatin, etoposide and bleomycin and one cycle of PE, cisplatin and etoposide.
  • Then he was given one more cycle of VIP therapy (etoposide, ifosfamide, cisplatin), but the serum AFP level was increased to 56 ng/ml.
  • Then, two cycles of chemotherapy with paclitaxel, ifosfamide and cisplatin were administered as salvage chemotherapy, which led to a normalization of the serum AFP level, and disappearance of the brain and spleen metastases.
  • Three years after his final hospitalization, the patient has had no evidence of recurrence or metastasis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Brain Neoplasms / secondary. Cisplatin / administration & dosage. Humans. Ifosfamide / administration & dosage. Lung Neoplasms / secondary. Male. Neoplasm Metastasis. Paclitaxel / administration & dosage. Salvage Therapy. Splenic Neoplasms / secondary. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Testicular cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260360.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 0 / alpha-Fetoproteins; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


2. Yasuhara T, Tamiya T, Meguro T, Ichikawa T, Sato Y, Date I, Nakashima H, Ohmoto T: Glioblastoma with metastasis to the spleen--case report. Neurol Med Chir (Tokyo); 2003 Sep;43(9):452-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma with metastasis to the spleen--case report.
  • The patient underwent surgery, focal irradiation, and chemotherapy.
  • The histological diagnosis was glioblastoma.
  • Four months after the operation, the patient again developed headache and left homonymous hemianopsia in addition to vomiting and mild left hemiparesis.
  • The patient underwent a second craniotomy and placement of a ventriculoperitoneal shunt.
  • The patient died of intraventricular dissemination 2 months after the second operation.
  • Autopsy revealed metastases in the spleen and lungs.
  • Glioblastoma with metastases to the spleen is very rare.
  • Excessive therapy should not be used for patients with extracranial metastases from glioblastoma.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / secondary. Splenic Neoplasms / secondary

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14560851.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Tang H, Huang H, Xiu Q, Shi Z: Isolated splenic metastasis from lung cancer: ringleader of continuous fever. Eur Respir Rev; 2010 Sep;19(117):253-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated splenic metastasis from lung cancer: ringleader of continuous fever.
  • The spleen is an infrequent metastatic organ of solid tumours, the prevalence of which ranges between 2.3% and 7.1% in populations with cancer as determined through autopsy.
  • The most common sources of metastasis are breast, lung, colorectal and ovarian carcinoma and melanoma.
  • Isolated metastasis of the spleen is rarely reported with only 93 cases from all sources having been reported up to 2007.
  • Therefore, isolated splenic metastasis from primary lung cancer is exceedingly rare with only 11 cases reported to date.
  • Herein, we report a rare case of isolated splenic metastasis in a 49-yr-old female 3 months after lobectomy for an undifferentiated large cell carcinoma in the right lung (pT(2a)N₀M₀).
  • This patient presented diagnostic challenges due to the presentation of high fever, leukoapenia after chemotherapy and the cystic splenic mass, all of which led to the initial consideration of splenic abscess.
  • The patient's high fever resolved rapidly after splenectomy and splenic metastasis was confirmed by pathological findings.
  • We also reviewed all 11 reported previously cases and summarised the characteristics and appropriate management of isolated splenic metastasis from lung cancer.
  • [MeSH-major] Carcinoma / secondary. Carcinoma, Large Cell / secondary. Fever / etiology. Lung Neoplasms / pathology. Splenic Neoplasms / secondary

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Fever.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20956202.001).
  • [ISSN] 1600-0617
  • [Journal-full-title] European respiratory review : an official journal of the European Respiratory Society
  • [ISO-abbreviation] Eur Respir Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


Advertisement
4. Goi T, Obata S, Murakami M, Hirono Y, Maeda H, Ishida M, Iida A, Katayama K, Yamaguchi A: [A case of recurrent colon cancer with urinary bladder, para-aortic lymph nodes, and spleen metastases successfully treated with CPT-11]. Gan To Kagaku Ryoho; 2007 Jan;34(1):109-11
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent colon cancer with urinary bladder, para-aortic lymph nodes, and spleen metastases successfully treated with CPT-11].
  • The patient was a 71-year-old woman with sigmoid colon cancer with urinary bladder invasion, for which sigmoidectomy with D 3 lymphadenectomy and partial cystectomy was performed.
  • After surgery, the patient was started on 4 courses of 6-week systemic chemotherapy (500 mg/m(2) 5-FU and 200 mg/m(2) l-LV weekly).
  • However, 4 months later, CT revealed local recurrence in the urinary bladder and recurrence in the para-aortic lymph nodes and spleen.
  • Therefore, low-dose CPT-11 therapy (40 mg/m(2) once per week) was instituted, which achieved a complete response as revealed by CT for response evaluation 5 months after the start of therapy.
  • The patient developed mild side effects such as grade 1 nausea, anorexia, and leukopenia, but has a well-maintained QOL.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / analogs & derivatives. Lymph Nodes / pathology. Sigmoid Neoplasms / drug therapy. Splenic Neoplasms / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Aorta. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Quality of Life. Remission Induction

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17220683.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


5. Egberts JH, Schniewind B, Pätzold M, Kettler B, Tepel J, Kalthoff H, Trauzold A: Dexamethasone reduces tumor recurrence and metastasis after pancreatic tumor resection in SCID mice. Cancer Biol Ther; 2008 Jul;7(7):1044-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dexamethasone reduces tumor recurrence and metastasis after pancreatic tumor resection in SCID mice.
  • Inflammation accompanies most solid cancers including pancreatic ductal adenocarcinoma (PDAC), one of the most fatal cancers with surgery being the only potential curative therapeutic.
  • DEX was administered after resection as an adjuvant treatment regime and 4 weeks later, local recurrent tumor sizes as well as number of liver and spleen metastases were analyzed.
  • In vivo, we observed a significant reduction of the local recurrent tumor volume and the number of liver and spleen metastases.
  • CONCLUSIONS: DEX has a profound influence on the malignant phenotype of PDAC tumor cells in vitro in terms of inhibition of invasiveness and pro-inflammatory signaling.
  • Therefore, DEX-treatment appears to be an interesting therapeutical option in an adjuvant setting after pancreatic cancer resection.
  • [MeSH-major] Dexamethasone / pharmacology. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Animals. Antineoplastic Agents, Hormonal / pharmacology. Cell Line, Tumor. Cell Proliferation. Female. Humans. Mice. Mice, SCID. Neoplasm Metastasis. Neoplasm Transplantation. Recurrence. Signal Transduction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2008 Jul;7(7):1051-2 [18698168.001]
  • (PMID = 18431088.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


6. Tamesa T, Watanabe Y, Yoshimura K, Mori N, Yamamoto S, Hazama S, Tangoku A, Oka M: [A case of disseminated tumor from cecal cancer with survival for over 5 years after twice surgical resection and systemic chemotherapy]. Gan To Kagaku Ryoho; 2004 Oct;31(11):1864-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of disseminated tumor from cecal cancer with survival for over 5 years after twice surgical resection and systemic chemotherapy].
  • A 66-year-old man underwent a curative operation for cecal cancer on the 30th of November, 1998.
  • Since his CEA level rose in January 2001, computed tomography (CT) revealed a tumor in the abdomen.
  • He received systemic chemotherapy (5'-DFUR 600 mg 3x everyday, CPT-11 80 mg/body div every 2 weeks), but the CEA level rose again in August 2003.
  • He was diagnosed with spleen metastasis and underwent splenectomy.
  • After that, he received systemic chemotherapy (5-FU 500 mg/body/week div, levofolinate calcium 250 mg/body/week i.v.) as an outpatient.
  • Peritoneal carcinomatosis from colorectal cancer with distant metastasis, in general, has no indication for an operation.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Camptothecin / analogs & derivatives. Cecal Neoplasms / therapy. Neoplasm Seeding. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Aged. Carcinoembryonic Antigen / blood. Combined Modality Therapy. Floxuridine / administration & dosage. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Reoperation

  • Hazardous Substances Data Bank. FLOXURIDINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553741.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 039LU44I5M / Floxuridine; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; V1JK16Y2JP / doxifluridine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Yamamoto A, Imai S, Gyoten M, Kajihara Y: [A case of thymic carcinoma responded to intra-arterial chemotherapy combined with radiation therapy]. Gan To Kagaku Ryoho; 2002 Nov;29(11):1967-70
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of thymic carcinoma responded to intra-arterial chemotherapy combined with radiation therapy].
  • For definitive diagnosis, biopsy was performed under CT guidance, and the patient was diagnosed as having anaplastic carcinoma in the thymus (T4, N1, M0, stage IVb).
  • Since surgical treatment was judged to be impossible because of infiltration into large blood vessels, the patient underwent chemotherapy by intra-arterial injection (CDDP, ADM) and radiotherapy (45 Gy), and obtained a CR.
  • Metastasis to the spleen was detected during the follow-up period, but a CR was obtained by chemotherapy by intra-arterial injection (CDDP) and systemic chemotherapy (TXL).
  • However, chemotherapy by intra-arterial injection of carcinostatics such as CDDP can be applied to patients in whom surgical treatment is impossible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / radiotherapy. Thymus Neoplasms / drug therapy. Thymus Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Humans. Injections, Intra-Arterial. Male. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12465397.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Tamaki T, Simada K, Tubakihara H, Tujimura H: [A case of gastric cancer with multiple liver metastases and spleen metastasis that responded to low-dose CDDP/TS-1 combination therapy]. Gan To Kagaku Ryoho; 2004 Jan;31(1):95-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gastric cancer with multiple liver metastases and spleen metastasis that responded to low-dose CDDP/TS-1 combination therapy].
  • Since the introduction of TS-1 for clinical treatment of the progression or recurrence of stomach cancer, the effectiveness of combination therapy incorporating other agents with CDDP has been reported.
  • Low-dose CDDP/TS-1 combination treatment was carried out in a case of Stage IV progressive stomach cancer showing multiple liver metastases and spleen metastasis.
  • Regression of the primary carcinoma and reduction in size of liver metastases and spleen metastasis were observed.
  • Grade 2 leukocyte decrease and grade 1 stomatitis were noted as adverse reactions to the treatment.
  • Low-dose CDDP/TS-1 combination therapy was useful in this case of advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Splenic Neoplasms / secondary. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Combinations. Humans. Male. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14750330.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Kinoshita K, Minami T, Ohmori Y, Kanayama S, Yoshikawa K, Tsujimura T: Curative resection of a small cell carcinoma of the pancreas: report of a case of long survival without chemotherapy. J Gastroenterol Hepatol; 2004 Sep;19(9):1087-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curative resection of a small cell carcinoma of the pancreas: report of a case of long survival without chemotherapy.
  • Computed tomography and magnetic resonance imaging showed a slightly enhanced heterogeneous mass, measuring about 5 cm in diameter, adjacent to the pancreas tail and spleen.
  • On abdominal angiography the tumor was found to be fed by the splenic artery, and no encasement was observed.
  • At operation the tumor was connected to the pancreas tail and attached to the spleen, and no metastasis was evident.
  • On histological examination the tumor cells had no ductal or architectural organization and were continuous to the normal pancreatic tissues.
  • In previously reported cases curative resection of the tumor had not been possible because of its rapid progression and metastasis, and the prognosis is generally very poor.
  • In our case, however, curative resection of the tumor was done, and the patient is healthy with no signs of recurrence for 56 months after the operation and with no additional therapy.
  • [MeSH-minor] Adult. Diagnosis, Differential. Diagnostic Imaging. Humans. Immunohistochemistry. Male. Pancreatectomy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15304133.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 33
  •  go-up   go-down


10. Ogura M, Tanaka N, Furuya T, Nomura Y, Nagai M, Takahashi M, Takayama T, Hirao H, Nakamura H, Suzuki Y: [A case of long-term survival after undergoing S-1 treatment and splenectomy for liver, lung and splenic metastases following curative distal gastrectomy for gastric cancer]. Gan To Kagaku Ryoho; 2010 Jun;37(6):1125-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of long-term survival after undergoing S-1 treatment and splenectomy for liver, lung and splenic metastases following curative distal gastrectomy for gastric cancer].
  • A 7 0-year-old female underwent distal gastrectomy for gastric cancer in November 2001.
  • She did not wish to receive postoperative adjuvant chemotherapy.
  • CT demonstrated liver(S5/6)and lung(S9)metastases in August 2002.
  • We started to treat her with S-1(100mg/day day 1-14 orally), and restaging CT showed complete regression of liver and lung metastases in August 2003.
  • In spite her complete response(CR), we continued S-1 treatment for the successive two years.
  • No adverse reaction to chemotherapy occurred.
  • Although CR was maintained for about 4 years, she was found to have a 9-mm solitary lesion in the upper pole of the spleen in June 2007.
  • After 6 months, this tumor increased to 15mm in size, and we considered it as a solitary metastasis to the spleen from gastric cancer.
  • S-1 chemotherapy was restarted, but tumor size gradually increased.
  • From then until now, she has not received any chemotherapy, and has been followed well without any recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Splenic Neoplasms / drug therapy. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Combinations. Female. Gastroenterostomy. Humans. Neoplasm Metastasis. Remission Induction. Splenectomy. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20567121.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


11. Hama N, Marubashi S, Dono K, Kobayashi S, Kim C, Asaoka T, Takeda Y, Nagano H, Umeshita K, Monden M, Doki Y, Mori M: [A long-term survival case of hepatocellular carcinoma recurrence after the patient received a living donor liver transplantation treated by combined modality therapy]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2092-5
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long-term survival case of hepatocellular carcinoma recurrence after the patient received a living donor liver transplantation treated by combined modality therapy].
  • We report a case of hepatocellular carcinoma (HCC) recurrence after the patient received a living donor liver transplantation, which was treated by combined modality therapy.
  • Then, multiple HCC recurred in the liver graft and the patient was treated by systemic chemotherapy, and local therapy such as RFA, PEIT and TAE.
  • Now 67 months after the transplantation, he additionally has a HCC metastasis to the spleen and lung and is treated by combined modality therapy.
  • This case suggested that a combined modality therapy might have improved the survival of the patient after recurrence in the liver transplantation for advanced HCC.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Lung Neoplasms / blood. Lung Neoplasms / drug therapy. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Middle Aged. Recurrence. Time Factors. Tomography, X-Ray Computed. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106534.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins
  •  go-up   go-down


12. Gogas H, Ignatiadis T, Markopoulos Ch, Karageorgopoulou S, Floros D, Vaiopoulos G: Solitary spleen metastasis and amyloidosis in a patient with endometrial cancer. Eur J Gynaecol Oncol; 2004;25(3):391-3
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary spleen metastasis and amyloidosis in a patient with endometrial cancer.
  • BACKGROUND: In contrast to autopsy findings, solitary splenic metastases from solid tumors are extremely rare.
  • Secondary amyloidosis is also found in malignancy.
  • CASE: A 52-year-woman originally diagnosed with a Stage IB, grade 2 endometrial carcinoma presented two and a half years later with a paroxysmal non-productive cough, weakness, loss of appetite and daily afternoon fever.
  • Histologic examination showed solitary spleen metastasis with amyloidosis.
  • As the patient had received a full course of postoperative irradiation after a total abdominal hysterectomy, six cycles of combination chemotherapy were administered.
  • CONCLUSION: A case of solitary spleen metastasis with amyloidosis in a patient with endometrial cancer is presented.
  • [MeSH-major] Amyloidosis / etiology. Endometrial Neoplasms / diagnosis. Splenic Neoplasms / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15171329.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


13. Bonardi S, Bottini A, Sperone P, Brizzi MP, Allevi G, Berruti A, Generali D, Aguggini S, Bernardi C, Dogliotti L: Chemotherapy followed by surgery of residual disease in metastatic breast cancer: A single institution prospective study. J Clin Oncol; 2004 Jul 15;22(14_suppl):766

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy followed by surgery of residual disease in metastatic breast cancer: A single institution prospective study.
  • : 766 Background: Response to chemotherapy in metastatic breast cancer patients is recognised as an important prognostic factor and may lead to a better selection of patients to be addressed to surgery.
  • METHODS: From 1990 to 2001, 328 consecutive patients with metastatic breast cancer were submitted to systemic therapy with anthracycline containing regimens.
  • One hundred fifty-seven patients (48.3%) had bone metastases, 130 (40.0%) lung, 93 (28.0%) liver, 123 (37.7%) skin/lymphnodes, 3 (12.5%) brain and 16 (4.9%) other sites of disease.
  • Nine (47.4%) of them had liver metastases, 6 (31.6%) lung, 3 (15.8%) bone, and 1 (5.3%) spleen metastases.
  • Median time to progression in radically resected patients was higher [91.4 months (ms)] as compared to overall population (10.9 ms) and to the patient subset attaining a disease response (13.6 ms).
  • All patients with radically resected metastatic bone disease showed disease progression in bone, whereas the patient with spleen metastasis had liver progression.
  • Among the 9 patients with liver metastases radically operated, 3 did not progress, 4 progressed in liver, 2 in bone, and 1 in lung.
  • In patients with radically resected lung metastases, 3 did not progress, 1 progressed in bone, 1 in lung and 1 in liver.
  • CONCLUSIONS: Radical surgery of metastatic breast cancer is associated to long survival but is feasible in a very few proportion of patients.
  • This treatment modality is not curative but sometimes it may change the natural history of the disease, as suggested by the recurrence in bone after removal of visceral metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014150.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Pizzirusso F, Gillet JP, Fobe D: Isolated spleen metastatic involvement from a colorectal adenocarcinoma complicated with a gastrosplenic fistula. A case report and literature review. Acta Chir Belg; 2004 Apr;104(2):214-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated spleen metastatic involvement from a colorectal adenocarcinoma complicated with a gastrosplenic fistula. A case report and literature review.
  • We present the case of a 66-year-old man with a moderately differentiated adenocarcinoma of the left colon and isolated spleen metastases, complicated with a gastrosplenic fistula.
  • The patient underwent a palliative segmental resection of the primitive colic tumour, as no curative treatment could be offered in view of the spleen involvement.
  • Adjuvant chemotherapy was started.
  • After a few chemotherapy treatments, he developed a gastrosplenic fistula which required the resection of the spleen and the greater gastric curvature together.
  • At the end of the chemotherapy course, all carcinologic features had also disappeared.
  • [MeSH-major] Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Gastric Fistula / etiology. Splenic Diseases / etiology. Splenic Neoplasms / secondary. Stomach Neoplasms / secondary
  • [MeSH-minor] Aged. Humans. Male. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15154583.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 9
  •  go-up   go-down


15. Cavallaro A, Modugno P, Specchia M, Pontenza AE, Loschiavo V, Colli R, Lauriola L, Barone C: Isolated splenic metastasis from colon cancer. J Exp Clin Cancer Res; 2004 Mar;23(1):143-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated splenic metastasis from colon cancer.
  • Solid-tumor metastases of the spleen are rare and usually associated with disseminated disease.
  • There are only seven reports in literature of isolated splenic metastases from colorectal carcinoma, which generally metastasize to regional lymphonodes, liver and abdominal peritoneum.
  • We report a case of isolated splenic metastasis in a 55-year-old woman who had undergone left hemicolectomy, lymphadenectomy and chemotherapy 18 months earlier for adenocarcinoma of the sigmoid colon with positive pericolic and inter-aortocaval lymphonodes.
  • This is the eighth documented case of isolated splenic metastasis from colon cancer.
  • Previously reported cases of this type are reviewed along with the mechanism underlying neoplastic spread to the spleen.
  • [MeSH-major] Colonic Neoplasms / pathology. Neoplasm Metastasis. Spleen / pathology. Splenic Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Sigmoid Neoplasms / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15149163.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Busić Z, Cupurdija K, Kolovrat M, Cavka V, Cavka M, Patrlj L, Servis D, Kvesić A: Isolated splenic metastasis from colon cancer--case report and literature review. Coll Antropol; 2010 Mar;34 Suppl 1:287-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated splenic metastasis from colon cancer--case report and literature review.
  • Solitary splenic metastases are very rare and sporadic.
  • There are several explanations for this low incidence of splenic metastasis including anatomical, histological and immunological features of the spleen.
  • In this paper we present a case of 70-year-old man with no history of previous diseases who was first operated under the diagnosis of acute abdomen revealing perforated colon tumor of splenic flexure with no metastases at that time.
  • Patient was referred to oncologist and received chemotherapy (5FU, Leucovorin).
  • 2 years after first surgical procedure, a CT scan and abdominal ultrasound, followed by needle biopsy, showed isolated metastasis in spleen, so splenectomy was performed.
  • Pathological findings revealed sharply bordered, partially necrotic tumor inside of spleen tissue, spreading to, but not reaching splenic hilum.
  • Histology showed low to medium differentiated adenocarcinoma tissue with desmoplastic stromal reaction.
  • There were no protrusions of tumor cells through spleen surface.
  • In splenic hilum 4 tumor free lymph nodes were harvested.
  • No additional chemotherapy was conducted.
  • The latest follow up, a year after diagnosis of metastasis showed no signs of cancer disease.
  • Review of the literature showed that long term survival and prognosis of isolated splenic colorectal metastasis after splenectomy are rather optimistic, although these are the cases of distant metastasis.
  • Due to small number of cases reported in literature, definitive conclusions and/or guidelines for the treatment of isolated splenic metastasis cannot be given, but splenectomy and chemotherapy are preferable in the treatment, promising long term survival at least for metachronous metastasis.
  • [MeSH-major] Colonic Neoplasms / pathology. Splenic Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20402335.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


17. Brammer RD, Taniere P, Radley S: Metachronous squamous-cell carcinoma of the colon and treatment of rectal squamous carcinoma with chemoradiotherapy. Colorectal Dis; 2009 Feb;11(2):219-20
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous squamous-cell carcinoma of the colon and treatment of rectal squamous carcinoma with chemoradiotherapy.
  • The patient developed a metastasis in the spleen and a further squamous tumour in the right colon, both of which were successfully resected.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Colonic Neoplasms / secondary. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy. Splenic Neoplasms / secondary
  • [MeSH-minor] Female. Humans. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18477022.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Zacarías Fluck MF, Rico MJ, Gervasoni SI, Ilarregui JM, Toscano MA, Rabinovich GA, Scharovsky OG: Low-dose cyclophosphamide modulates galectin-1 expression and function in an experimental rat lymphoma model. Cancer Immunol Immunother; 2007 Feb;56(2):237-48
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Galectin-1 (Gal-1), a member of a family of highly conserved beta-galactoside-binding proteins, has been recently shown to contribute to tumor cell evasion of immune responses by modulating survival and differentiation of effector T cells.
  • Here we show that administration of a single low-dose cyclophosphamide (Cy), which is capable of restraining metastasis in the rat lymphoma model L-TACB, can also influence Gal-1 expression in primary tumor, metastasis, and spleen cells and modulate the effects of this protein on T cell survival.
  • A time-course study revealed a positive correlation between Gal-1 expression and tumor volume in primary tumor cells.
  • Conversely, Gal-1 expression was significantly reduced in spleen cells and lymph node metastasis throughout the period studied.
  • Interestingly, cyclophosphamide treatment was capable of restoring the basal levels of Gal-1 expression in primary tumors and spleens.
  • In addition, this antimetastatic agent rendered spleen T cells from tumor-bearing animals resistant to Gal-1-induced cell death.
  • Our results suggest that, in addition to other well-known functions of cyclophosphamide, this immunomodulatory agent may also modulate Gal-1 expression and function during tumor growth and metastasis with critical implications for tumor-immune escape and immunotherapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacology. Cyclophosphamide / pharmacology. Galectin 1 / drug effects. Lymphoma / drug therapy. Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blotting, Western. Dose-Response Relationship, Drug. Female. Immunohistochemistry. Lymphatic Metastasis / pathology. Rats. T-Lymphocytes / drug effects. T-Lymphocytes / immunology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733672.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Galectin 1; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


19. Roomi MW, Kalinovsky T, Roomi NW, Ivanov V, Rath M, Niedzwiecki A: Suppression of growth and hepatic metastasis of murine B16FO melanoma cells by a novel nutrient mixture. Oncol Rep; 2008 Oct;20(4):809-17
Hazardous Substances Data Bank. L-Lysine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of growth and hepatic metastasis of murine B16FO melanoma cells by a novel nutrient mixture.
  • Highly metastatic melanoma is resistant to existing therapies.
  • Our main objective was to investigate the effect of a nutrient mixture (NM) on B16FO tumor growth and hepatic metastasis.
  • Metastasis was studied in C57BL/6 mice, which received 10(6) B16FO melanoma cells by intrasplenic injection, as well as a regular or 0.5% NM-supplemented diet for 2 weeks.
  • Survival was studied in C57BL/6 mice receiving 10(6) B16FO melanoma cells intraperitoneally (i.p.) followed by the regular, NM-supplemented, or regular diet in addition to being administered with 2 mg NM injection 3 times per week.
  • Lesions in the two groups were consistent with malignant melanoma.
  • Mice were injected with B16FO cells in the spleen.
  • Those fed the regular diet developed large black spleens and livers indicating growth in the spleen and metastasis to the liver.
  • In contrast, mice supplemented with NM showed less growth in spleen, but also reduced metastasis to the liver.
  • The survival time of mice receiving NM supplementation and B16FO cells i.p. was greater than in mice which were fed the regular diet.
  • To confirm effects in vivo, we investigated the effect of NM on murine B16FO melanoma cells in vitro, including cell proliferation by MTT assay, morphology by hematoxylin and eosin (H&E) staining and apoptosis using live green caspase detection kit.
  • [MeSH-major] Ascorbic Acid / administration & dosage. Liver Neoplasms, Experimental / secondary. Lysine / administration & dosage. Melanoma, Experimental / drug therapy. Plant Extracts / administration & dosage. Proline / administration & dosage. Tea
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Proliferation / drug effects. Male. Mice. Mice, Inbred C57BL

  • MedlinePlus Health Information. consumer health - Vitamin C.
  • Hazardous Substances Data Bank. Green tea .
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18813822.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Tea; 9DLQ4CIU6V / Proline; K3Z4F929H6 / Lysine; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


20. Lauro S, Trasatti L, Capalbo C, Conti A, Ricci F, Mingazzini PL, Vecchione A: Solitary splenic recurrence of epithelial ovarian cancer: a case report and review. Anticancer Res; 2002 Nov-Dec;22(6B):3643-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary splenic recurrence of epithelial ovarian cancer: a case report and review.
  • The metastatic involvement of the spleen in epithelial ovarian cancer is rare and usually reflects late disseminated disease.
  • Isolated parenchymal metastasis in the spleen is an extremely unusual event, in fact in most cases in medical literature, the spleen was involved as part of diffuse peritoneal carcinomatosis.
  • We report a rare case of epithelial ovarian carcinoma, which recurred in the splenic parenchyma 15 years after initial treatment.
  • The patient underwent a splenectomy followed by six cycles of platinum-based poly-chemotherapy.
  • In the solitary splenic recurrence of epithelial ovarian cancer our case suggests that accurate surgical resection of the spleen, followed by platinum-based chemotherapy, is correlated with a prolonged survival.
  • [MeSH-major] Adenocarcinoma / secondary. Ovarian Neoplasms / pathology. Splenic Neoplasms / secondary

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12552970.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


21. Yoon TJ, Kim TJ, Lee H, Shin KS, Yun YP, Moon WK, Kim DW, Lee KH: Anti-tumor metastatic activity of beta-glucan purified from mutated Saccharomyces cerevisiae. Int Immunopharmacol; 2008 Jan;8(1):36-42
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-tumor metastatic activity of beta-glucan purified from mutated Saccharomyces cerevisiae.
  • To examine the antitumor and immunostimulating activities of beta-glucan (IS-2) purified from mutated S. cerevisiae, we made an experiment on innate immune response against metastasis of cancer cells by comparing with the beta-glucan from wild-type S. cerevisiae.
  • In experimental lung metastasis of colon 26-M3.1 carcinoma or B16-BL6 melanoma cells, prophylactic administration of beta-glucan purified from mutated S. cerevisiae significantly inhibited lung metastasis in a dose-dependent manner.
  • Furthermore, therapeutic administration of IS-2 also significantly inhibited the colon 26-M3.1 cell growth in mice.
  • In an assay of liver and spleen metastasis produced by i.v. inoculation of L5178Y-ML25 lymphoma cells, IS-2 also significantly inhibited metastasis in CDF1 mice.
  • Furthermore, pretreatment with IS-2 two days before tumor inoculation significantly prolonged the survival time of tumor-bearing mice.
  • In addition, treatment with IS-2 (20 microg/mouse) induced tumoricidal activity of peritoneal macrophages against colon 26-M3.1 cells.
  • In an assay for natural killer (NK) cell activity, IS-2 (20 microg/mouse, i.v.) significantly augmented NK cytotoxicity against Yac-1 tumor cells at 2 days after IS-2 treatment.
  • The depletion of NK cells by injection of rabbit anti-asialo GM1 serum abolished the inhibitory effect of IS-2 on lung metastasis of colon 26-M3.1 cells.
  • These data suggest that IS-2 inhibits tumor metastasis via activation of macrophages and NK cells.
  • [MeSH-major] Lung Neoplasms / secondary. Lung Neoplasms / therapy. Mutagenesis. Saccharomyces cerevisiae / genetics. beta-Glucans / isolation & purification. beta-Glucans / therapeutic use
  • [MeSH-minor] Animals. Cell Line, Tumor. Coculture Techniques. Female. Leukemia L5178 / therapy. Melanoma, Experimental / metabolism. Melanoma, Experimental / therapy. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Rabbits

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068098.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / beta-Glucans
  •  go-up   go-down


22. Yoon TJ, Yoo YC, Kang TB, Song SK, Lee KB, Her E, Song KS, Kim JB: Antitumor activity of the Korean mistletoe lectin is attributed to activation of macrophages and NK cells. Arch Pharm Res; 2003 Oct;26(10):861-7
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inhibitory effect of the lectins (KML-C) isolated from Korean mistletoe (KM; Viscum album coloratum) on tumor metastases produced by murine tumor cells (B16-BL6 melanoma, colon 26-M3.1 carcinoma and L5178Y-ML25 lymphoma cells) was investigated in syngeneic mice.
  • An intravenous (i.v.) administration of KML-C (20-50 ng/mouse) 2 days before tumor inoculation significantly inhibited lung metastases of both B16-BL6 and colon 26-M3.1 cells.
  • The prophylactic effect of 50 ng/mouse of KML-C on lung metastasis was almost the same with that of 100 microg/mouse of KM.
  • Treatment with KML-C 1 day after tumor inoculation induced a significant inhibition of not only the experimental lung metastasis induced by B16-BL6 and colon 26-M3.1 cells but also the liver and spleen metastasis of L5178Y-ML25 cells.
  • Furthermore, multiple administration of KML-C given at 3 day-intervals after tumor inoculation led to a significant reduction of lung metastasis and suppression of the growth of B16-BL6 melanoma cells in a spontaneous metastasis model.
  • In an assay for natural killer (NK) cell activity, i.v. administration of KML-C (50 ng/mouse) significantly augmented NK cytotoxicity against Yac-1 tumor cells 2 days after KML-C treatment.
  • In addition, treatment with KML-C (50 ng/mouse) induced tumoricidal activity of peritoneal macrophages against B16-BL6 and 3LL cells.
  • These results suggest that KML-C has an immunomodulating activity to enhance the host defense system against tumors, and that its prophylactic and therapeutic effect on tumor metastasis is associated with the activation of NK cells and macrophages.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Killer Cells, Natural / metabolism. Macrophage Activation / drug effects. Phytotherapy. Plant Lectins / isolation & purification. Plant Lectins / therapeutic use
  • [MeSH-minor] Animals. Cell Line, Tumor. Cytotoxicity, Immunologic / drug effects. Female. Korea. Lung Neoplasms / drug therapy. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Neoplasm Metastasis / drug therapy. Neoplasm Transplantation / methods. Neoplasms, Experimental / drug therapy. Plant Extracts / chemistry. Plant Extracts / therapeutic use. Plants, Medicinal / chemistry. Viscum album / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14609136.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Extracts; 0 / Plant Lectins
  •  go-up   go-down


23. Roomi MW, Kalinovsky T, Roomi NW, Monterrery J, Rath M, Niedzwiecki A: A nutrient mixture suppresses hepatic metastasis in athymic nude mice injected with murine B16FO melanoma cells. Biofactors; 2008;33(3):181-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A nutrient mixture suppresses hepatic metastasis in athymic nude mice injected with murine B16FO melanoma cells.
  • Highly metastatic melanoma is resistant to existing therapies.
  • A unique micronutrient mixture (NM) containing ascorbic acid, amino acids, green tea extract has been shown to exhibit anticancer activity in vivo and in vitro in a number of cancer cell lines including human and murine melanoma cells lines.
  • In this study we examined the effect of dietary NM supplementation on hepatic metastasis of intrasplenic injection of B16FO melanoma cells in athymic nude mice.
  • Athymic nude mice (n = 10), 10-12 weeks of age, received 10(6) B16FO melanoma cells by injection into the spleen and divided into two groups.
  • The Control mice developed large black spleens and livers indicating growth in the spleen and metastasis to the liver.
  • However, the mice supplemented with NM not only showed less tumor growth in the spleen as the Control mice, but also drastically reduced metastasis to the liver.
  • In all groups, no metastasis to the kidneys and lungs was evident.
  • In conclusion, these results suggest that NM has potential in suppression of tumor metastasis.
  • [MeSH-major] Cell Proliferation / drug effects. Dietary Supplements. Liver Neoplasms / secondary. Splenic Neoplasms / diet therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Male. Mice. Mice, Nude. Neoplasm Transplantation

  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19478422.001).
  • [ISSN] 0951-6433
  • [Journal-full-title] BioFactors (Oxford, England)
  • [ISO-abbreviation] Biofactors
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


24. Chen Y, Wu Q, Chen Z, Chen F, Su W: Effect of all-trans retinoic acid on growth of xenograft tumor and its metastasis in nude mice. Chin Med J (Engl); 2000 Apr;113(4):345-9
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of all-trans retinoic acid on growth of xenograft tumor and its metastasis in nude mice.
  • OBJECTIVE: To study the effect of all-trans retinoic acid on growth of xenograft tumor and its metastasis in nude mice.
  • METHODS: Human gastric cancer BGC-823 and MKN-45 cells were inoculated into spleen subcapsule of nude mice, respectively.
  • Xenograft tumors in spleen and metastatic tumors in liver were pathologically examined.
  • RESULTS: After the nude mice were fed with all-trans retinoic acid, the growth of splenic tumor and its liver metastasis were inhibited and the metastatic rates decreased by 50% (BGC-823) and 33.3% (MKN-45), respectively.
  • The microvessel density in splenic and hepatic tumors reduced by 28.58% and 35.47% (BGC-823), 19.45% and 14.52% (MKN-45), respectively.
  • CONCLUSION: All-trans retinoic acid may effectively inhibit the growth of xenograft tumor in spleen and its metastasis to liver in nude mice, which can be corroborated by the decrease of carcinoembryonic antigen and microvessel density.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Liver Neoplasms, Experimental / prevention & control. Liver Neoplasms, Experimental / secondary. Splenic Neoplasms / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Animals. Carcinoembryonic Antigen / analysis. Humans. Mice. Mice, Nude. Microcirculation / drug effects. Neoplasm Transplantation. Neovascularization, Pathologic / prevention & control. Transplantation, Heterologous. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11775233.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen; 5688UTC01R / Tretinoin
  •  go-up   go-down






Advertisement